Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

BCMA News

News
Subgroup of Patients With MM Show Lower T-Cell Count Against COVID-19
12/01/2021
A subgroup of patients with MM who received anti-BCMA or anti-CD38 therapies were found to have lower B and T-cell counts against SARS-CoV-2.
A subgroup of patients with MM who received anti-BCMA or anti-CD38 therapies were found to have lower B and T-cell counts against SARS-CoV-2.
A subgroup of patients with MM...
12/01/2021
Oncology
News
Low Dose GSI, BCMA CAR T-Cell Combo Yields Anti-Tumor Activity in R/R MM
11/10/2021
GSI combined with BCMA CAR T-cell treatment was shown to create deep, tolerable, and durable responses in patients with R/R MM; all data were presented at the 2021 ASH Meeting.
GSI combined with BCMA CAR T-cell treatment was shown to create deep, tolerable, and durable responses in patients with R/R MM; all data were presented at the 2021 ASH Meeting.
GSI combined with BCMA CAR...
11/10/2021
Oncology
News
Anti-BCMA CAR-T Cell Therapy Found Safe, Effective in Extramedullary MM
10/21/2021
Two phase 1 studies investigate the safety and efficacy of anti-BCMA CAR-T cell therapy for R/R patients with or without extramedullary MM and identify important risk factors.
Two phase 1 studies investigate the safety and efficacy of anti-BCMA CAR-T cell therapy for R/R patients with or without extramedullary MM and identify important risk factors.
Two phase 1 studies investigate...
10/21/2021
Oncology

Advertisement

News
Immune Deficiencies Present Following Anti-BCMA CAR-T Cell Therapy in R/R MM
10/04/2021
Researchers investigated recovery durations of patients with R/R multiple myeloma who received BCMA CAR-T cell therapy. Results confirm immune and hematologic deficiencies after treatment.
Researchers investigated recovery durations of patients with R/R multiple myeloma who received BCMA CAR-T cell therapy. Results confirm immune and hematologic deficiencies after treatment.
Researchers investigated...
10/04/2021
Oncology
News
Teclistamab Shows Potential Activity in BCMA-Positive MM
09/30/2020
Data support further examination of teclistamab therapy in the context of patients with MM and BCMA expression.
Data support further examination of teclistamab therapy in the context of patients with MM and BCMA expression.
Data support further examination...
09/30/2020
Oncology
News
Combined Anti-CD19 and Anti-BCMA CAR-T Therapy Feasible for Relapsed/Refractory MM
08/14/2019
The combined use of humanized anti-CD19 and anti-BCMA CAR T-cells is feasible for patients with relapsed or refractory multiple myeloma.
The combined use of humanized anti-CD19 and anti-BCMA CAR T-cells is feasible for patients with relapsed or refractory multiple myeloma.
The combined use of humanized...
08/14/2019
Oncology

Advertisement

News
New CAR-T Therapy Less Toxic, More Effective for MM Than Other CAR-Ts
11/29/2018
P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.
P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.
P-BCMA-101, a novel CAR-T...
11/29/2018
Oncology
News
Novel CAR-T Drug Promising in Relapsed or Refractory MM
09/11/2018
A new stem cell memory CAR-T therapy has demonstrated exceptional efficacy and safety in patients with relapsed and/or refractory multiple myeloma.
A new stem cell memory CAR-T therapy has demonstrated exceptional efficacy and safety in patients with relapsed and/or refractory multiple myeloma.
A new stem cell memory CAR-T...
09/11/2018
Oncology
News
CAR T-Cells Targeting BCMA Improve Outcomes in MM
03/27/2018
Multiple studies have demonstrated positive results for CAR T-cells in treating relapsed and refractory MM.
Multiple studies have demonstrated positive results for CAR T-cells in treating relapsed and refractory MM.
Multiple studies have...
03/27/2018
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use